CoChat

Are SGLT2 Inhibitors Ready for Prime Time for CKD?

Open access
Pecoits-Filho, Roberto, Perkovic, Vlado · 2018 · Clinical Journal of the American Society of Nephrology
Cited by 33

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Introduction Sodium-glucose cotransporter-2 (SGLT2) is a sodium-dependent glucose transport protein, and its inhibitors (SGLT2i - gliflozins) are indicated as an adjunct therapy to diet and exercise for improving glycemic control in type 2 diabetes mellitus (DM2). In fact, SGLT2i usage has been associated with a robust hemoglobin A1c (HbA1c) reduction of 0.5%–0.6%, sustained over 52 weeks of follow-up (1). Because of their unique mechanism of action, SGLT2i have a range of effects that may translate to potential benefits beyond glycemic control, including BP and weight reduction. A meta-analysis assessing effects on BP, indicated a 2.46 mm Hg reduction in systolic BP following treatment with SGLT2i. The mean difference in diastolic BP was 1.46 mm Hg, and in body weight was 1.88 kg (2). Interestingly, these factors are clearly associated with the risk of not only cardiovascular (CV) disease, but kidney disease also. This article reviews the current and forthcoming knowledge relating to clinical trials of SGLT2i and its effect on kidney disease. Main Kidney Findings in the Published Clinical Trials SGLT2i consistently cause an acute reduction in GFR by approximately 5 ml/min per 1.73 m2, as well as a consistent 30%–40% reduction in albuminuria (3). The GFR effect led to initial concern that SGLT2i may increase the risk of AKI. These data support mechanistic studies that suggest proximal tubular natriuresis activates tubule-glomerular feedback through increased macula densa sodium delivery, leading to afferent arteriole vasoconstriction and reduction in intraglomerular pressure (4). As the glycosuric effects are dependent on glomerular filtration, it is not surprising that these effects are attenuated in patients with a reduced GFR. In contrast, BP lowering, albuminuria lowering effects, and impact on eGFR are preserved in patients with CKD. These data suggest that SGLT2i may have beneficial kidney effects, even in people with reduced kidney function, where glycemic benefits are limited (5). Interestingly, a recent study suggested that canagliflozin slows the progression of kidney function decline independently of effects on glycemia (6). These observations motivated the development of clinical trials to test the hypothesis that SGLT2i may be a kidney protective treatment. Two major studies describing the impact of the drugs on long-term kidney outcomes have been reported. In combination with other ongoing clinical trials (Table 1), these studies may shift the therapeutic paradigm in diabetic kidney disease, and perhaps other progressive kidney diseases, expanding the options available to patients. Table 1. - Comparative description of the major SGLT2i studies including a kidney endpoint Name Of the Study EMPA-REG OUTCOME CANVAS/CANVAS R DECLARE VERTIS CREDENCE DAPA-CKD EMPAGLIFLOZIN RENAL Clinical trial registration NCT01131676 NCT01032629 and NCT01989754 NCT01730534 NCT01986881 NCT02065791 NCT03036150 TBA Intervention Empagliflozin versus placebo Canagliflozin versus placebo Dapagliflozin versus placebo Ertugliflozin versus placebo Canagliflozin versus placebo Dapagliflozin versus placebo Empagliflozin versus placebo Patient population DM2, high CV risk DM2, high CV risk DM2, high CV risk DM2, established vascular disease DM2, high CV risk DM2 and nonpatients with diabetes, high CV risk DM2 and nonpatients with diabetes, high CV risk Kidney function inclusion criteria eGFR≥30 ml/min per 1.73 m2 eGFR≥30 ml/min per 1.73 m2 eGFR≥30 ml/min per 1.73 m2 eGFR≥30 ml/min per 1.73 m3 30≥ eGFR≤90 ml/min per 1.73 m2 (CKD 2 and 3) 30≥ eGFR≤90 ml/min per 1.73 m3 (CKD 2 and 3) 30≥ eGFR≤90 ml/min per 1.73 m4 (CKD 2 and 3) Number of patients 7021 10,142 17,276 8000 (estimated) 4461 4000 (estimated) TBA Prespecified renal endpoints Incident or worsening nephropathy (progression to macroalbuminuria, doubling of the serum creatinine level, initiation of RRT, or death from renal disease) and incident albuminuria Progression to albuminuria, sustained 40% reduction in the eGFR, the need for RRT, or death from renal causes Time to first event of renal composite endpoint: Confirmed sustained ≥40% decrease in eGFR to eGFR<60 ml/min per 1.73 m2 and/or ESRD and/or renal or CV death Time to composite of renal death, renal dialysis/transplant, or ≥2×increase in baseline serum creatinine Time to the first occurrence of an event in the primary composite endpoint (primary) ESRD, doubling of serum creatinine, renal or CV death Time to the first occurrence of any of the components of the composite: ≥50% sustained decline in eGFR or reaching ESRD or CV death or renal death TBA Outcomes A 44% relative risk reduction of doubling of SCr (1.5% versus 2.6%); 38% relative risk reduction of progression to macroalbuminuria (11.2% versus 16.2%); 55% relative risk reduction of initiation of RRT (0.3% versus 0.6%); slowing GFR decline (annual decrease 0.19±0.11 versus 1.67±0.13 ml/min per 1.73 m2; P<0.001). Reduction in the progression of albuminuria (ha

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2215/cjn.07680717

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 6

  1. Monami, 2014, Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials, Diabetes Obes Metab, 16, 457, 10.1111/dom.12244 · DOI · Paper page
  2. Wu, 2016, Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: A systematic review and meta-analysis, Lancet Diabetes Endocrinol, 4, 411, 10.1016/S2213-8587(16)00052-8 · DOI · Paper page
  3. Petrykiv, 2017, Differential effects of dapagliflozin on cardiovascular risk factors at varying degrees of renal function, Clin J Am Soc Nephrol, 12, 751, 10.2215/CJN.10180916 · DOI · Paper page
  4. Wanner, 2016, Empagliflozin and progression of kidney disease in type 2 diabetes, N Engl J Med, 375, 323, 10.1056/NEJMoa1515920 · DOI · Paper page
  5. Wanner, 2016, Empagliflozin and progression of kidney disease in type 2 diabetes, N Engl J Med, 375, 1801, 10.1056/NEJMoa1515920 · DOI · Paper page
  6. Neal, 2017, Canagliflozin and cardiovascular and renal events in type 2 diabetes, N Engl J Med, 377, 644, 10.1056/NEJMoa1611925 · DOI · Paper page

Cited by

Metadata

Authors
Pecoits-Filho, R., & Perkovic, V.
Venue
Clinical Journal of the American Society of Nephrology
Published
2017-09-11
Volume
13
Issue
2
Pages
318-320
ISSN
  • 1555-9041 (ISSN-L)
  • 1555-905X
OpenAlex
W2754469738
Cited by
33
References
3
FWCI
4.75
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.